CompletedPhase 2NCT02158520
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
Studying Uveal melanoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Academic and Community Cancer Research United
- Principal Investigator
- Svetomir N Markovic, M.DAcademic and Community Cancer Research United
- Intervention
- Bevacizumab(biological)
- Enrollment
- 24 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2019
Study locations (13)
- Saint Mary's Medical Center, San Francisco, California, United States
- Mayo Clinic in Florida, Jacksonville, Florida, United States
- University of Illinois, Chicago, Illinois, United States
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
- Siouxland Regional Cancer Center, Sioux City, Iowa, United States
- Cancer Research Consortium of West Michigan NCORP, Grand Rapids, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States
- Missouri Valley Cancer Consortium, Omaha, Nebraska, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay, Wisconsin, United States
- University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02158520 on ClinicalTrials.govOther trials for Uveal melanoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07364474Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the LiverMassachusetts General Hospital
- RECRUITINGPHASE3NCT07015190Neoadjuvant Darovasertib in Primary Uveal MelanomaIDEAYA Biosciences
- RECRUITINGPHASE2NCT07276386Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal MelanomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGPHASE1, PHASE2NCT06961357Clinical Trial of CD40L-augmented TIL for Patients With Advanced MelanomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGPHASE1NCT07203391Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell HomeostasisSt Vincent's Hospital, Sydney
- RECRUITINGPHASE1NCT07076550A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic MelanomaAlpha-9 Oncology USA Inc.
- RECRUITINGNCT07421739Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) SubjectsAura Biosciences
- RECRUITINGPHASE1, PHASE2NCT06626516Tebentafusp-tebn With LDT in Metastatic UMThomas Jefferson University